Tag Archives: “GLIOBLASTOMA MULTIFORME (GBM)”

[1] – 1991 (10/4/1991) – Site visit – Antineoplaston Cases

Posted on by
Reply

This page is linked to:
=====================================
Critiquing: Dr. Michael A. Friedman, Dr. Mark G. Malkin, Dr. Mario Sznol, Robert B. Lanman, Memorial Sloan-Kettering Cancer Center, Mayo Clinic, Department of Health & Human Services (HHS), Public Health Service, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Center (NCI) at the National Institutes of Health (NIH), Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/08/critiquing-stanislaw-burzynski-on-the-arrogance-of-ignorance-about-cancer-and-targeted-therapies/
======================================
[1] – 1991 (10/4/1991) – Site visit – Antineoplaston Cases (1 pg.)
——————————————————————
1. Histology partial lobe glioblastoma multiforme (GBM)
Size 2.3 cm largest diameter
Response Complete Response (CR) possible
prior Treatment (Tx) Radiation Therapy (RT), surgery

2. Histology anaplastic astrocytoma stage IV grade 3
Size 3.0 tumor 3.5 tumor and edema
Response CR possible
prior Treatment (Tx) Radiation Therapy (RT)

3. Histology infiltrating glioma (astrocytoma or mixed astrocytoma / oligodendroglioma)
Size 4.4
Response good PR, possible CR
prior Treatment (Tx) Radiation Therapy (RT) and BUdR; Procarbazine, CCNU, VCR; B-Interferon; DFMO and MGBG

4. Histology well differentiated Stage IV astrocytoma, possible juvenile pilocytic astrocytoma
Size 5.5 X 3.3
Response 40-50% decrease of solid component
prior Treatment (Tx) vitamins and laetrile

5. Histology glioblastoma multiforme (GBM)
Size 6.5 x 5.0
Response 39% decrease
prior Treatment (Tx) Radiation Therapy (RT)

6. Histology glioma consistent with anaplastic astrocytoma (AA), differential: anaplastic astrocytoma or spindle cell variant of oligodendroglioma
Size 5.1 x 2.2
Response Complete Response (CR)
prior Treatment (Tx) Radiation Therapy (RT)

7. Histology Infiltrating anaplastic astrocytoma (AA)
Size 4.0 (L) 4.8 (bifrontal)
Response good response – possible Complete Response (CR)
prior Treatment (Tx) Radiation Therapy (RT)

20130912-191141.jpg
======================================
1991 (10/4/1991) – site visit [3]
======================================

Burzynski: GLIOBLASTOMA MULTIFORME (GBM)

Posted on by
Reply

� � � � � � � � � � � � � � � � �
# and % of Patients Resolving or Stabilizing Disease = Complete Response + Partial Response + Stable Disease
——————————————————————
14 / 63.5 – 10/2004 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME (GBM) which recurred or progressed post surgery, radiation therapy, and / or chemotherapy
======================================
# and % of Patients Showing Objective Response = Complete Response + Partial Response
——————————————————————
2 / 9% – 10/2004 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME (GBM) which recurred or progressed post surgery, radiation therapy, and / or chemotherapy
======================================
# and % of Patients Showing Complete Response
——————————————————————
1 / 4.5% – 10/2004 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME (GBM) which recurred or progressed post surgery, radiation therapy, and / or chemotherapy
======================================
# and % of Patients Showing Partial Response
——————————————————————
1 / 4.5% – 10/2004 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME (GBM) which recurred or progressed post surgery, radiation therapy, and / or chemotherapy
======================================
# and % of Patients Showing Stable Disease
——————————————————————
12 / 54.5% – 10/2004 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME (GBM) which recurred or progressed post surgery, radiation therapy, and / or chemotherapy
======================================
# and % of Patients Showing Progressive Disease
——————————————————————
8 / 36.5% – 10/2004 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME (GBM) which recurred or progressed post surgery, radiation therapy, and / or chemotherapy
� � � � � � � � � � � � � � � � �

� � � � � � � � � � � � � � � � �
Maximum Survival (MS):
——————————————————————
26% – 6/1/2003 Antineoplastons – Protocol – GLIOBLASTOMA MULTIFORME 3/2004 (Pg. 48)
======================================
17+ years – 6/1/2003 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME 3/2004 (Pg. 48)
�
11+ years – 6/1/2003 – Protocol – GLIOBLASTOMA MULTIFORME (Pg. 54)
======================================
1 Surviving who exhibited Objective Response (OR):
——————————————————————
11+ years – 6/1/2003 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME 2004 (Pg. 55)
======================================
Surviving:
——————————————————————
9+ years – 6/1/2003 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME 2004 (Pg. 55)
======================================
Maximum Overall Survival:
——————————————————————
8+ years – 10/2004 recurrent GLIOBLASTOMA MULTIFORME (GBM) (Pgs. 384-385)
======================================
2 Patients have been Surviving Post Diagnosis:
——————————————————————
7+ years – 6/1/2003 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME 2004 (Pg. 55)
======================================
Median Overall Survival from start of Treatment (OST) with the Majority of Patients Alive:
——————————————————————
5.1 years – 6/1/2003 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME 3/2004 (Pg. 48)
======================================
5 year Progression-Free Survival (PFS):
——————————————————————
34 / 26% – GLIOBLASTOMA MULTIFORME (GBM): after radical surgery – 1998 Protocol: High-Grade ASTROCYTOMA – Surgery: Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 1998; 89: 52-9 131 (Pg. 171 + 176) 2006
======================================
5 year Progression-Free Survival (PFS):
——————————————————————
5 / 4% – GLIOBLASTOMA MULTIFORME (GBM): less aggressive surgery – 1998 Protocol: High-Grade ASTROCYTOMA – Surgery: Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 1998; 89: 52-9 131 (Pg. 171 + 176) 2006
======================================
3 Surviving:
——————————————————————
3 years approximately – 6/1/2003 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME 2004 (Pg. 55)
======================================
% of Objective Response (OR) Patients hadn’t Progressed:
——————————————————————
53% – 6/1/2003 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME (Pg. 54)
======================================
Progression-Free Survival (PFS):
——————————————————————
2 years – 1 Patient – Progressed after 24 months 6/1/2003 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME 3/2004 (Pg. 48)
======================================
Median Overall Survival from Diagnosis (OSD):
——————————————————————
15 months (1 year 3 months) –
======================================
Median Survival:
——————————————————————
15 months (1 year 3 months) – 6/1/2003 Antineoplastons: Protocol – glioma of the highest malignancy, recurrent GLIOBLASTOMA MULTIFORME (GBM) (Pg. 55)
�
6.5 months (26.9 weeks) – 4/2003 recurrent GLIOBLASTOMA MULTIFORME (GBM) with newest forms of Chemotherapy (Prados et al.). 62 – carboplatin + x (Pg. 58)
�
4 months 3.9 weeks (19.9 weeks) – 4/2003 recurrent GLIOBLASTOMA MULTIFORME (GBM) with newest forms of Chemotherapy (Prados et al.). 60 – carboplatin + placebo (Pg. 58)
======================================
Median Overall Survival:
——————————————————————
9.2 months – 10/2004 recurrent GLIOBLASTOMA MULTIFORME (GBM)
======================================
Median Overall Survival from start of Treatment (OST):
——————————————————————
9 months – 6/1/2003 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME (Pg. 54)
======================================
Newest forms of chemotherapy:
——————————————————————
Less than 7 months – 6/1/2003 (2004) (Pg. 55)
======================================
Progression-Free Survival (PFS):
——————————————————————
11 / 50% – 6 months – 10/2004 recurrent GLIOBLASTOMA MULTIFORME (GBM)
======================================
Progression-Free Survival (PFS):
——————————————————————
5 months – 6/1/2003 Antineoplastons: Protocol – GLIOBLASTOMA MULTIFORME (Pg. 54)
======================================
no treatment
——————————————————————
4 months – (Pg. 58)
======================================
Median Survival – Untreated Patients:
——————————————————————
4 months – 6/1/2003 (2004) (Pg. 55)
Deceased or Status Unknown:
======================================
� � � � � � � � � � � � � � � � �

� � � � � � � � � � � � � � � � �
Burzynski: Complete Response, Partial Response, Stable Disease, Progressive Disease, Objective Response, and Response:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-complete-response-partial-response-stable-disease-progressive-disease-objective-response-and-response/
� � � � � � � � � � � � � � � � �
Burzynski: Progression-Free Survival:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-progression-free-survival/
� � � � � � � � � � � � � � � � �